logo
Plus   Neg
Share
Email

Novartis Receives Positive CHMP Opinion For Mayzent To Treat SPMS

Novartis (NVS) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA adopted a positive opinion for Mayzent for the treatment of adult patients with secondary progressive multiple sclerosis or SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.

It is estimated that up to 80% of patients will eventually transition from relapsing remitting multiple sclerosis or RRMS to secondary progressive multiple sclerosis or SPMS.

CHMP opinion is based on the Phase III EXPAND trial, the largest randomized clinical study in a broad SPMS patient population.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
eBay Inc. (EBAY) Wednesday reported a fourth-quarter profit that trumped Wall Street analysts' estimates, as did revenues. However, shares of the company slipped over 5% after the company issued a weak outlook for the first quarter. eBay's fourth-quarter profit dropped to $558 million or $0.69 per... Apple Inc. (AAPL) Wednesday reported a first-quarter profit that trumped Wall Street estimates, as the iPhone maker reported its "highest quarterly revenue ever" driven by strong demand for its iPhone 11 and 11 Pro models during the holiday season. The tech giant also issued a strong revenue outlook... New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry.
Follow RTT
>